Marshall S. Baker, M.D.

Marshall S. Baker, M.D.

Marshall S. Baker, M.D.

Log into NorthShoreConnect

Profile

Conditions & Procedures

Conditions

Abscess, Appendix, Cyst, Gallbladder, Gallbladder Disease, Hernia, Lipoma, Liver, Liver Cancer, Melanoma, Pancreaticobiliary Disease, Sarcoma, Skin Lesion

Procedures

Bile Duct Surgery, Biliary Surgery, Colon, Colon/Rectal Surgery, General Surgery, Hepatobiliary and Oncologic Surgery, Hepatobiliary Surgery, Liver and Biliary Oncologic Surgery, Liver Surgery, Minimally Invasive Hernia Surgery, Minimally Invasive Stomach, Oncologic Surgery, Pancreas Surgery and Management, Pancreatic Cancer and Disease Management, Pancreatic Surgery, Peritoneal Dialysis (PD) Catheter, Port-a-cath, Surgical Oncology, Temporal Artery Biopsy

General Information

Gender

Male

Affiliation

NorthShore Medical Group

Expertise

General Surgery, Oncologic Surgery, Pancreatic Cancer

Academic Rank

Clinical Assistant Professor

Languages

English

Board Certified

Surgery

Clinical Service

Surgical Oncology

Education, Training & Fellowships

Medical School

Dartmouth Medical School, 1998

Internship

Georgetown University Hospital, 2000

Residency

Northwestern Feinberg School of Medicine, 2006

Fellowship

Northwestern Feinberg School of Medicine, 2003
Indiana University School of Medicine, 2007

Locations

A

NorthShore Medical Group

1000 Central St.
Suite 800
Evanston, IL 60201
847.570.1700 847.570.1330 fax This location is wheelchair accessible.
B

NorthShore Medical Group

2050 Pfingsten Rd.
Suite 128
Glenview, IL 60026
847.570.1700 847.570.1330 fax This location is wheelchair accessible.
C

NorthShore Medical Group

225 N. Milwaukee Ave.
Suite 1500
Vernon Hills, IL 60061
847.570.1700 847.570.1330 fax This location is wheelchair accessible.
D

NorthShore Medical Group

2650 Ridge Ave.
Kellogg Cancer Center
Evanston, IL 60201
847.570.1700 847.570.1330 fax This location is wheelchair accessible.

Insurance

Every effort has been made to ensure the accuracy of the information in this directory. However, some changes may occur between updates. Please check with your provider to ensure that he or she participates in your health plan.

Aetna HMO/PPO/POS
BCBS HMOI
BCBS PPO *except Blue Choice IL
Beechstreet PPO
CCN PPO
CIGNA Choice Fund
CIGNA Choice Fund PPO
CIGNA EPO
CIGNA Network
CIGNA Network Open Access
CIGNA POS
CIGNA POS Open Access
CIGNA PPO
CIGNA:Open Access Plus
Community Care Partners
First Health PPO
Galaxy PPO
Great West POS
Great West PPO
Healthcares Finest Network PPO
Humana Choice Care PPO
Humana IPA--HMO
Humana POS
Humana PPO
Land of Lincoln
Medicare
Multiplan Admar PPO
Multiplan Formost PPO
Multiplan Health Network PPO
Multiplan Wellmark PPO
NorthShore Employee Network I (EPO Option)
NorthShore Employee Network II (EPO Plus & CDHP)
PHCS PPO
Preferred Plan PPO
Railroad Medicare - Cook County
UHC *except Core & Navigate
Unicare PPO

Publications

  • Surgical Resection Provides an Overall Survival Benefit for Patients with Small Pancreatic Neuroendocrine Tumors.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2014 Aug 26

    Authors: Sharpe SM,
    Abstract
    The optimal management of small (≤2 cm) pancreatic neuroendocrine tumors (PNETs) remains controversial. We evaluated these tumors in the National Cancer Data Base (NCDB) to determine if resection provides a survival advantage over observation.
    The NCDB was queried to identify patients with nonmetastatic PNETs ≤2 cm treated between 1998 and 2006. Kaplan-Meier survival estimates, stratified by grade and treatment type, evaluated the difference in 5-year overall survival (OS) between patients who underwent resection and observation. Multivariable Cox regression was used to determine the importance of resection in OS.
    Three hundred eighty patients met inclusion criteria. Eighty-one percent underwent resection; 19 % were observed. Five-year OS was 82.2 % for patients who underwent surgery and 34.3 % for those who were observed (p < 0.0001). When controlling for age, comorbidities, income, facility type, tumor size and location, grade, margin status, nodal status, surgical management, and nonsurgical therapy in the Cox model, observation [hazard ratio (HR) 2.80], poorly differentiated histology (HR 3.79), lymph node positivity (HR 2.01), and nonsurgical therapies (HR 2.23) were independently associated with an increase in risk of mortality (p < 0.01).
    Patients with localized PNETs ≤2 cm had an overall survival advantage with resection compared to observation, independent of age, comorbidities, tumor grade, and treatment with nonsurgical therapies.
    PMID: 25155459 [PubMed - as supplied by publisher]
  • Using a modification of the Clavien-Dindo system accounting for readmissions and multiple interventions: defining quality for pancreaticoduodenectomy.

    Journal of surgical oncology 2014 Sep

    Authors: Baker MS,
    Abstract
    The Clavien-Dindo system (CD) does not change the grade assigned a complication when multiple readmissions or interventions are required to manage a complication. We apply a modification of CD accounting for readmissions and interventions to pancreaticoduodenectomy (PD).
    PDs done between 1999 and 2009 were reviewed. CD grade IIIa complications requiring more than one intervention and II and IIIa complications requiring significantly prolonged lengths of stay including all 90-day readmissions were classified severe-adverse-postoperative-outcomes (SAPO). CD IIIb, IV, and V complications were also classified SAPOs. All other complications were considered minor-adverse-postoperative-outcomes (MAPO).
    Four-hundred forty three of 490 PD patients (90.4%) had either no complication or a complication of low to moderate CD grade (I, II, IIIa). When reclassified by the new metric, 92 patient-outcomes (19%) were upgraded from CD II or IIIa to SAPO. One-hundred thirty nine patients (28.4%) had a SAPO. Multivariable regression identified age >75 years, pylorus preservation and operative blood loss >1,500 ml as predictors of SAPO. Age was not associated with poor outcome using the unmodified CD system.
    Established systems may under-grade the severity of some complications following PD. We define a procedure-specific modification of CD accounting for readmissions and multiple interventions. Using this modification, advanced age, pylorus preservation, and significant blood loss are associated with poor outcome.
    PMID: 24861871 [PubMed - as supplied by publisher]
  • Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.

    Surgery 2013 Oct

    Authors: Cherenfant J,
    Abstract
    The biologic potential of nonfunctioning pancreatic neuroendocrine tumors (PNETs) is highly variable and difficult to predict before resection. This study was conducted to identify clinical and pathologic factors associated with malignant behavior and death in patients diagnosed with PNETs.
    We used International Classification of Diseases 9th edition codes to identify patients who underwent pancreatectomy for PNETs from 1998 to 2011 in the databases of 4 institutions. Functioning PNETs were excluded. Multivariate regression Cox proportional models were constructed to identify clinical and pathologic factors associated with distant metastasis and survival.
    The study included 128 patients-57 females and 71 males. The age (mean ± standard deviation) was 55 ± 14 years. The body mass index was 28 ± 5 kg/m(2). Eighty-nine (70%) patients presented with symptoms, and 39 (30%) had tumors discovered incidentally. The tumor size was 3.3 ± 2 cm with 56 (44%) of the tumors measuring ≤2 cm. Seventy-three (57%) patients had grade 1 histology tumors, 37 (29%) had grade 2, and 18 (14%) had grade 3. Peripancreatic lymph node involvement was present in 31 patients (24%), absent in 75 (59%), and unknown in 22 (17%). Distant metastasis occurred in 18 patients (14%). There were 12 deaths, including 1 perioperative, 8 disease related, and 3 of unknown cause. With a median follow-up of 33 months, the overall 5-year survival was 75%. Multivariate Cox regression analysis identified age >55 (hazard ratio [HR], 5.89; 95% confidence interval [CI], 1.64-20.58), grade 3 histology (HR, 6.08; 95% CI, 1.32-30.2), and distant metastasis (HR, 8.79; 95% CI, 2.67-28.9) as risk factors associated with death (P < .05). Gender, race, body mass index, clinical symptoms, lymphovascular and perineural invasion, and tumor size were not related to metastasis or survival (P > .05). Three patients with tumors ≤2 cm developed distant metastasis resulting in 2 disease-related deaths.
    Age >55 years, grade 3 histology, and distant metastasis predict a greater risk of death from nonfunctioning PNETs. Resection or short-term surveillance should be considered regardless of tumor size.
    PMID: 24074416 [PubMed - as supplied by publisher]
  • CA 19-9 Nonproduction Is Associated With Poor Survival After Resection of Pancreatic Adenocarcinoma.

    American journal of clinical oncology 2013 Feb 20

    Authors: Hayman AV,
    Abstract
    BACKGROUND:: Carbohydrate antigen (CA) 19-9 is the most common serum biomarker used in pancreatic adenocarcinoma (PC). Elevated preoperative levels have been shown to correlate with more advanced stage, greater risk of unresectability, and overall worse survival. The prognostic value of CA 19-9 nonproduction, which is present in an estimated 5% to 15% of the population, is unclear. We sought to determine whether CA 19-9 nonproduction was associated with worse survival after PC resection. METHODS:: We retrospectively reviewed our institution's prospective pancreatic database for all PC patients with documented preoperative CA 19-9 values who underwent resection with curative intent from March 1992 to August 2009. After excluding 10 perioperative deaths, 200 patients remained for analysis. RESULTS:: Mean and median follow-up was 23.3 and 16.1 months, respectively. Median survival in months for patients with preoperative CA 19-9 levels in U/mL by category was as follows: normal (5.1 to 36.9): 32, nonproduction (≤5): 21, mildly elevated (37 to 99.9): 35, highly elevated (100+): 16. Factors significantly associated with worse overall survival were: nonwhite race, nonproduction or highly elevated preoperative CA 19-9 (≥100 U/mL), estimated blood loss ≥1 L, tumor size (≥2 cm), lymph node-positivity, and advanced (3/4) histologic grade. On multivariate analysis, only CA 19-9 nonproduction or highly elevated production, estimated blood loss ≥1 L, advanced histologic grade, and node positivity remained significant in the final model. CONCLUSIONS:: CA 19-9 nonproduction is not associated with improved survival after pancreatic cancer resection, as has previously been asserted, when compared with patients with normal and elevated levels.
    PMID: 23428954 [PubMed - as supplied by publisher]
  • Proceedings of the 46th annual Pancreas Club meeting.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2013 Mar

    Authors: Baker MS,
    Abstract
    The 46th annual Pancreas Club meeting was held on May 18 and 19 at the Hyatt Regency Mission Bay in San Diego, California. A brief summary of the meeting including an overview in table form is presented below.
    PMID: 23297027 [PubMed - as supplied by publisher]
  • Defining quality for distal pancreatectomy: does the laparoscopic approach protect patients from poor quality outcomes?

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2013 Feb

    Authors: Baker MS,
    Abstract
    Established systems for grading postoperative complications do not change the assigned grade when multiple interventions or readmissions are required to manage a complication. Studies using these systems may misrepresent outcomes for the surgical procedures being evaluated. We define a quality outcome for distal pancreatectomy (DP) and use this metric to compare laparoscopic distal pancreatectomy (LDP) to open distal pancreatectomy (ODP).
    Records for patients undergoing DP between January 2006 and December 2009 were reviewed. Clavien-Dindo grade IIIb, IV, and V complications were classified as severe adverse--poor quality--postoperative outcomes (SAPOs). II and IIIa complications requiring either significantly prolonged overall lengths of stay including readmissions within 90 days or more than one invasive intervention were also classified as SAPOs.
    By Clavien-Dindo system alone, 91 % of DP patients had either no complication or a low/moderate grade (I, II, IIIa) complication. Using our reclassification, however, 25 % had a SAPO. Patients undergoing LDP demonstrated a Clavien-Dindo complication profile identical to that for SDP but demonstrated significantly shorter overall lengths of stay, were less likely to require perioperative transfusion, and less likely to have a SAPO.
    Established systems undergrade the severity of some complications following DP. Using a procedure-specific metric for quality, we demonstrate that LDP affords a higher quality postoperative outcome than ODP.
    PMID: 23225109 [PubMed - as supplied by publisher]
  • Summary of at the 45th annual Pancreas Club meeting proceedings.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2012 May

    Authors: Zyromski NJ,
    Abstract
    The 45th meeting of the Pancreas Club was held on 5 and 6 May 2011 at the Robert H. Lurie Medical Research Center in Chicago, IL. An outstanding program of 47 oral presentations (Table 1) and 137 poster presentations was chosen from a record number of submitted abstracts. Ten posters each day were chosen for presentation as part of the Professor Rounds portion of the formal poster viewing program. Summaries of the oral presentations are provided; published work is referenced. Full abstracts are available on the Pancreas Club website: http://pancreasclub.com.
    PMID: 22362070 [PubMed - as supplied by publisher]
  • Adding days spent in readmission to the initial postoperative length of stay limits the perceived benefit of laparoscopic distal pancreatectomy when compared with open distal pancreatectomy.

    American journal of surgery 2011 Mar

    Authors: Baker MS,
    Abstract
    Published comparisons of laparoscopic (laparoscopic distal pancreatectomy [LDP]) to open distal pancreatectomy (ODP) identify improved lengths of stay (LOS) after LDP but do not include data on readmissions.
    Demographic, operative, and postoperative outcomes data for patients undergoing LDP or ODP between August 2007 and December 2009 were culled from our prospectively accruing pancreatic database. Electronic medical records were reviewed to determine cause, treatment, and LOS for readmissions.
    Patients undergoing LDP were statistically identical to those undergoing ODP in regard to age, presentation, demographic characteristics, comorbidities, operative times, tumor sizes, morbidity, mortality, and pancreatic fistula rates. The initial LOS was statistically shorter for those undergoing LDP (4.8 ± .1 days vs 8.7 ± .1 days, P < .001). The readmission rate for LDP was statistically higher than for ODP (25% vs 8%, P < .05). Overall LOS for LDP was 7.2 ± .3 days versus 9.3 ± .1 days for ODP (P = .2).
    Adding readmission LOS to initial LOS eliminates the perceived effect of LDP to accelerate recovery.
    PMID: 21367366 [PubMed - as supplied by publisher]
  • Laparoscopic distal pancreatectomy using radiofrequency energy.

    American journal of surgery 2010 Mar

    Authors: Fronza JS,
    Abstract
    The pancreatic remnant remains a significant source of morbidity during laparoscopic pancreatectomy. Previous series have relied heavily on the endoscopic stapler for transection. Our study is the first to report use of a laparoscopic radiofrequency device for pancreatic transection.
    The laparoscopic Habib 4x delivers high-energy radio waves through a hand-held device consisting of 4 electrodes and allows for bloodless tissue transection. We retrospectively evaluated prospectively collected data. Fourteen patients were identified and used in our analysis.
    There were no conversions, blood transfusions, reoperations, or mortalities. Average length of stay was 4.6 days. There was 1 readmission. Clinically significant fistula occurred in 2 patients (14%), only one of which required an intervention.
    Radiofrequency energy is safe and feasible for use during laparoscopic pancreatic transection. Moreover, it is technically simple to use.
    PMID: 20226919 [PubMed - as supplied by publisher]
  • Neoadjuvant therapy for pancreatic cancer: a current review.

    Journal of surgical oncology 2010 Mar 15

    Authors: Abbott DE,
    Abstract
    The optimal therapy for pancreatic cancer continues to evolve. Neoadjuvant chemoradiation is a key component of current treatment regimens, and evaluation of previous treatment options will help guide future trials. Here the authors present a review of the current literature with discussion of future directions.
    PMID: 20187063 [PubMed - as supplied by publisher]
× Alternate Text